A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer

The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better controlling the growth of brain lesions in people with brain metastases from their cancer.

Start Date09 Oct 2014

Sponsor / Collaborator

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+1]

NCT02133846

/ CompletedPhase 1IIT

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy

The purpose of this study is to determine the safety and tolerability [maximum tolerated dose (MTD) within planned dosing range] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with primary four repeat tauopathies (4RT), corticobasal syndrome (CBS; also called corticobasal degeneration, CBD) or progressive supranuclear palsy (PSP).

Start Date01 May 2014

Sponsor / Collaborator

The University of California, San Francisco

[+2]

NCT02047214

/ TerminatedPhase 2

Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen

The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following prior radiation and temozolomide (TMZ) therapy and that has progressed following prior bevacizumab therapy.

Start Date01 Jan 2014

Sponsor / Collaborator

Cortice Biosciences, Inc.

100 Clinical Results associated with ARC-100

100 Translational Medicine associated with ARC-100

100 Patents (Medical) associated with ARC-100

Literatures (Medical) associated with ARC-100

01 Jan 2024·Neuro-oncology advances

Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma

Article

Author: Benkers, Tara ; Hsu, Sigmund ; Singer, Samuel ; Duic, Paul J ; Rao, Mayank ; Nabors, Louis B ; Goldlust, Samuel A ; Silberman, Sandra L ; Mohile, Nimish ; Cappello, Lori ; Farmer, George

Abstract:

Background:

Recurrent glioblastoma (rGBM) has limited treatment options. This phase 1 protocol was designed to study the safety and preliminary efficacy of TPI 287, a central nervous system penetrant microtubule stabilizer, in combination with bevacizumab (BEV) for the treatment of rGBM.

Methods:

GBM patients with up to 2 prior relapses without prior exposure to anti-angiogenic therapy were eligible. A standard 3 + 3 design was utilized to determine the maximum tolerated dose (MTD) of TPI 287. Cohorts received TPI 287 at 140–220 mg/m2 every 3 weeks and BEV 10 mg/kg every 2 weeks during 6-week cycles. An MRI was performed after each cycle, and treatment continued until progression as determined via response assessment in neuro-oncology criteria.

Results:

Twenty-four patients were enrolled at 6 centers. Treatment was generally well tolerated. Fatigue, myelosuppression, and peripheral neuropathy were the most common treatment emergent adverse events. Dose-limiting toxicity was not observed, thus the MTD was not determined. Twenty-three patients were evaluable for median and 6-month progression-free survival, which were 5.5 months (mo) and 40%, respectively. Median and 12-month overall survival were 13.4 mo and 64%, respectively. The optimal phase 2 dose was determined to be 200 mg/m2.

Conclusions:

TPI 287 can be safely combined with BEV for the treatment of rGBM and preliminary efficacy supports further investigation of this combination.

01 Feb 2023·Cancer chemotherapy and pharmacology

The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo

Article

Author: Lehman, Norman L ; Teer, Landon ; Hey, Andrew J ; Williams, Brian J ; Kakar, Aastha ; Schier, Leslie M ; Sak, Müge ; Chen, Joseph ; Al-Kawaaz, Mustafa N G ; Wilson, Megan J ; Zumbar, Cory T

INTRODUCTION:

Glioblastoma (GBM) has a very poor prognosis despite current treatment. We previously found cytotoxic synergy between the AURKA inhibitor alisertib and the CNS-penetrating taxane TPI 287 against GBM tumor cells in vitro.

METHODS:

We used an orthotopic human GBM xenograft mouse model to test if TPI 287 potentiates alisertib in vivo. Western blotting, immunohistochemistry, siRNA knockdown, annexin V binding, and 3-dimensional Matrigel invasion assays were used to investigate potential mechanisms of alisertib and TPI 287 treatment interactions.

RESULTS:

Alisertib + TPI 287 combination therapy significantly prolonged animal survival compared to vehicle (p = 0.011), but only marginally compared to alisertib alone. Alisertib, TPI 287, and combined alisertib + TPI 287 reduced animal tumor volume compared to vehicle-treated controls. This was statistically significant for the combination therapy at 4 weeks (p < 0.0001). Alisertib + TPI 287 treatment decreased anti-apoptotic Bcl-2 protein levels in vivo and in vitro. Expression of the pro-apoptotic protein Bak was significantly increased by combination treatment (p < 0.0001). Pro-apoptotic Bim and Bak knockdown by siRNA decreased apoptosis by alisertib + TPI 287 in GB9, GB30, and U87 cells (p = 0.0005 to 0.0381). Although alisertib and TPI 287 significantly reduced GBM cell invasion (p < 0.0001), their combination was no more effective than TPI 287 alone.

CONCLUSIONS:

Results suggest that apoptosis is the dominant mechanism of potentiation of GBM growth inhibition by alisertib + TPI 287, in part through effects on Bcl-2 family proteins, providing a rationale for further laboratory testing of an AURKA inhibitor plus TPI 287 as a potential therapy against GBM.

01 Feb 2020·JAMA neurologyQ1 · MEDICINE

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome

Q1 · MEDICINE

Article

Author: Geldmacher, David S. ; Koestler, Mary ; Powers, Ryan ; Hare, Emma ; Shamloo, Merhdad ; Jung, Joo In ; Rosen, Howard J. ; Tsai, Richard M. ; Chuu, Emmeline L. ; Luong, Phi N. ; Mumford, Paige ; Rabinovici, Gil D. ; Wolf, Amy ; Boxer, Adam L. ; Miller, Zachary ; Ljubenkov, Peter A. ; Miller, Bruce L. ; Natelson-Love, Marissa ; Fagan, Anne M. ; Cobigo, Yann ; Wang, Ping ; Rojas, Julio C. ; McKinley, Emily C. ; Roberson, Erik D. ; Brown, Jesse A.

Importance:

Basket-design clinical trials that allow investigation of treatment effects on different clinical syndromes that share the same molecular pathophysiology have not previously been attempted in neurodegenerative disease.

Objective:

To assess the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 (abeotaxane) in Alzheimer disease (AD) or the 4-repeat tauopathies (4RT) progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).

Design, Setting, and Participants:

Two parallel-design, double-blind, placebo-controlled phase 1 randomized clinical trials in AD and 4RT were conducted from December 20, 2013, through May 4, 2017, at the University of California, San Francisco, and University of Alabama at Birmingham. A total of 94 patients with clinically diagnosed AD (n = 39) and 4RT (n = 55) were screened; of these, 3 refused to participate, and 10 with AD and 11 with 4RT did not meet inclusion criteria. A total of 29 patients with AD, 14 with PSP, and 30 with β-amyloid-negative CBS (determined on positron emission tomography findings) were enrolled. Data were analyzed from December 20, 2013, through May 4, 2017, based on modified intention to treat.

Interventions:

Randomization was 8:3 drug to placebo in 3 sequential dose cohorts receiving 2.0, 6.3, or 20.0 mg/m2 of intravenous TPI-287 once every 3 weeks for 9 weeks, with an optional 6-week open-label extension.

Main Outcomes and Measures:

Primary end points were safety and tolerability (maximal tolerated dose) of TPI-287. Secondary and exploratory end points included TPI-287 levels in cerebrospinal fluid (CSF) and changes on biomarker, clinical, and neuropsychology measures.

Results:

A total of 68 participants (38 men [56%]; median age, 65 [range, 50-85] years) were included in the modified intention-to-treat analysis, of whom 26 had AD (14 women [54%]; median age, 63 [range, 50-76] years), and 42 had 4RT (16 women [38%]; median age, 69 [range, 54-83] years). Three severe anaphylactoid reactions occurred in TPI-287-treated patients with AD, whereas none were seen in patients with 4RT, leading to a maximal tolerated dose of 6.3 mg/m2 for AD and 20.0 mg/m2 for 4RT. More falls (3 in the placebo group vs 11 in the TPI-287 group) and a dose-related worsening of dementia symptoms (mean [SD] in the CDR plus NACC FTLD-SB [Clinical Dementia Rating scale sum of boxes with frontotemporal dementia measures], 0.5 [1.8] in the placebo group vs 0.7 [1.6] in the TPI-287 group; median difference, 1.5 [95% CI, 0-2.5]; P = .03) were seen in patients with 4RT. Despite undetectable TPI-287 levels in CSF, CSF biomarkers demonstrated decreased chitinase-3-like protein-1 (YKL-40) levels in the 4RT treatment arm (mean [SD], -8.4 [26.0] ng/mL) compared with placebo (mean [SD], 10.4 [42.3] ng/mL; median difference, -14.6 [95% CI, -30.0 to 0.2] ng/mL; P = .048, Mann-Whitney test).

Conclusions and Relevance:

In this randomized clinical trial, TPI-287 was less tolerated in patients with AD than in those with 4RT owing to the presence of anaphylactoid reactions. The ability to reveal different tau therapeutic effects in various tauopathy syndromes suggests that basket trials are a valuable approach to tau therapeutic early clinical development.

Trial Registration:

ClinicalTrials.gov identifiers: NCT019666666 and NCT02133846.

News (Medical) associated with ARC-100

12 Aug 2026

·www.biospace.com

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / ACCESS Newswire / August 12, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2026 and provided an update on the corporate strategy the company introduced in March 2026. "We are moving with speed and discipline to transform this company," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. "In the second quarter, we significantly strengthened our balance sheet and added new expertise to our Board to enable us to build a differentiated, high-value pipeline of innovative therapies. We are executing with urgency and are confident that the actions we've taken this year strengthen CNS Pharmaceuticals ability to create meaningful value going forward." Strategic and Corporate Highlights ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); New corporate strategy in motion. Since announcing its strategic pivot in March 2026 beyond a singular focus on glioblastoma multiforme, the Company has been leveraging its executive team's multi-functional experience across high-value therapeutic areas. As previously stated, the Company expects to in-license or acquire one or more assets by year end 2026. Oversubscribed $22.5 million financing closed. On May 5, 2026, the Company closed a private placement with institutional investors, including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners, generating approximately $22.5 million in gross proceeds ($20.7 million net), significantly reinforcing the Company's capital and shareholder base in support of its new strategy. Board strengthened with dealmaking depth. The Company appointed Michal Fisher, a life sciences executive with a track record in business development, licensing and capital formation, including prior leadership roles in strategic alliances and corporate development to its Board of Directors in May 2026. Legacy programs advancing toward closure. The Company's global clinical trial of Berubicin for glioblastoma is complete. The Company is now focused on closing out the study while pursuing out-licensing discussions for both Berubicin and TPI 287. Since announcing its new corporate strategy in March 2026, the Company has focused on leveraging the experience of its leadership team to identify promising development-stage therapeutic assets that align with its strategy of building a diversified pipeline targeting serious diseases. Management is actively evaluating business development opportunities while maintaining financial discipline and preserving capital for future growth initiatives. "This quarter reflects the deliberate work of resetting CNS Pharmaceuticals for its next chapter," said Steve O'Loughlin, Chief Financial Officer. "With a fortified balance sheet, extended capital runway, and new shareholder base comprised of biotech focused institutional investors, we are well positioned to execute our strategy with an enhanced ability to transact." Second Quarter 2026 Financial Results Cash and cash equivalents were approximately $20.0 million as of June 30, 2026, compared to $7.2 million as of December 31, 2025. The increase primarily reflects the Company's previously announced private placement financing completed in May 2026. The Company believes its existing cash resources are sufficient to fund planned operations beyond the next twelve months as it continues executing its strategic business development initiatives. Research and development expenses were approximately $1.2 million for the second quarter of 2026, compared to $1.2 million for the same period in 2025. Research and development expenses included activities related to completing and closing out the Berubicin clinical trial, as enrollment and patient treatment have been completed. Future research and development expenses will depend on the timing and nature of any assets the Company acquires or licenses and the associated development activities. General and administrative expenses were approximately $1.5 million for the second quarter of 2026, compared to $1.2 million for the same period in 2025. The increase was primarily attributable to higher headcount-related expenses, partially offset by lower professional services costs. Net loss for the second quarter of 2026 was approximately $2.6 million, or $0.37 per basic and diluted share, compared to a net loss of approximately $2.4 million, or $6.42 per basic and diluted share, for the second quarter of 2025. As of August 14, 2025, the Company had 1,461,449 common shares of stock outstanding and 10,604,928 shares fully diluted including pre-funded warrants that were issued in its May 2026 financing. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders. For more information, please visit , and connect with the Company on X and LinkedIn . Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the anticipated use of proceeds from the Company's recent $22.5 million financing, the Company's ability to identify and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and key milestones related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law. CONTACTS: Investor Relations Contact JTC Team, LLC Jenene Thomas 908.824.0775 CNSP@jtcir.com Business Development Contact CNS Pharmaceuticals, Inc. Dylan Wenke, Chief Business Officer dwenke@cnspharma.com SOURCE: CNS Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

Financial StatementExecutive Change

14 May 2026

·www.biospace.com

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy Company actively evaluating multiple acquisition opportunities while advancing discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287 New executive leadership team assembled in the first quarter continues to demonstrate rapid execution against strategy HOUSTON, TX / ACCESS Newswire / May 14, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting the Company's ongoing strategic transformation and execution progress. The first quarter of 2026 marked the beginning of a significant strategic shift for CNS Pharmaceuticals, including the appointment of a new Chief Executive Officer and executive leadership team, the launch of a new corporate strategy, the repositioning of the Company toward an acquisition-driven growth strategy focused on differentiated clinical-stage assets in neurology and oncology and the decision to seek out-licensing opportunities for its legacy glioblastoma multiforme programs, Berubicin and TPI-287. Subsequent to quarter end, CNS Pharmaceuticals completed a $22.5 million private placement with participation from several leading institutional healthcare investors. The proceeds from the private placement, together with existing cash, are intended to enable CNS Pharmaceuticals to identify, acquire, and advance differentiated assets with clear development and regulatory pathways that have clear inflection catalysts and the potential for near-term value creation. "We believe CNS Pharmaceuticals has entered a transformational new phase defined by strategic clarity, financial strength and disciplined execution," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. "Over the past several months, we have rebuilt the foundation of the Company by assemblinga highly experienced executive team, completed a rigorous strategic review, strengthened our balance sheet through an oversubscribed financing, initiated an aggressive search for differentiated clinical-stage assets capable of generating meaningful near-term catalysts and long-term shareholder value, and advanced discussions to out-license our legacy glioblastoma multiforme programs, Berubicin and TPI-287." Mr. Levin continued, "The current biotechnology environment continues to create compelling acquisition opportunities, particularly for companies with capital, operational experience and strategic focus. We believe CNS Pharmaceuticals is now positioned to capitalize on this environment as we rapidly work to build and diversify our pipeline with high-value programs that have clear development pathways and the potential to drive substantial value creation." Summary of Financial Results for the First Quarter 2026 General and administrative expense was approximately $1,431,000 for the three months ended March 31, 2026 compared to approximately $1,095,000 for the comparable period in 2025. The increase in general and administrative expense was primarily attributable to increased professional expenses related to the Company's strategic review that was conducted in collaboration with a leading life science focused advisory firm and placement services related to the Company's new executive leadership team. Research and development expense was approximately $3,544,000 for the three months ended March 31, 2026 compared to approximately $3,243,000 for the comparable period in 2025. The change in research and development expense during the period is primarily attributable to an increase in placement services and headcount expense. The net loss for the three months ended March 31, 2026 was approximately $4,936,000 compared to approximately $4,301,000 for the comparable period in 2025. The change in net loss is primarily attributable to increased research and development costs and an increase in professional expenses. Cash and cash equivalents were $2,951,000 as of March 31, 2026. The cash balance on March 31, 2026 does not account for the gross proceeds from the $22.5 million private placement closed on May 5, 2026. The Company expects these proceeds, together with existing cash resources, to fund operations beyond twelve months. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders. For more information, please visit , and connect with the Company on X and LinkedIn . Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the expected gross proceeds and closing of the private placement, the Company's intended use of proceeds from the private placement together with existing cash, the Company's pipeline prioritization and strategic development, the anticipated contributions of the new management team to the Company's growth, expectations regarding clinical development and regulatory strategy, the Company's ability to deliver meaningful value to patients and shareholders, and the Company's plans to explore out-licensing or strategic sales of legacy assets. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law. CONTACTS: Investor Relations Contact JTC Team, LLC Jenene Thomas 908.824.0775 CNSP@jtcir.com Business Development Contact CNS Pharmaceuticals, Inc. Dylan Wenke, Chief Business Officer dwenke@cnspharma.com SOURCE: CNS Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

Financial StatementExecutive ChangeAcquisition

11 Mar 2026

·www.fiercebiotech.com

CNS Pharma wipes glioblastoma pipeline clean in strategic pivot to fresh neurology, oncology targets

CNS Pharmaceuticals\' new approach is to bring in preclinical or clinical candidates with “defined value inflection points.”\n With a fresh leadership team settling in, CNS Pharmaceuticals is wiping its pipeline clean as it hunts for a new lead asset.After tapping a consulting firm for advice, the Houston-based biotech has elected to offload its glioblastoma candidates berubicin and TPI 287, the company announced in a March 11 release. CNS is now looking for partners that can take these assets off its hands while the company shops for promising new prospects in neurology and oncology.A phase 2 trial of berubicin in recurrent glioblastoma multiforme will continue through its expected completion in July, a spokesperson for CNS told Fierce Biotech this morning. The company had previously reported that berubicin failed to top fellow chemotherapy lomustine in this trial, though the study wasn’t powered to test for noninferiority.TPI 287, meanwhile, has not yet commenced its next phase of clinical development, according to the spokesperson, who explained that CNS won’t advance the asset any further. The biotech had previously said it planned to launch a phase 2 trial for the molecule, a derivative of the chemotherapy taxane.TPI 287 and berubicin are CNS\' only two assets, the spokesperson confirmed.The strategic pivot doesn’t come with any layoffs, the spokesperson added, and, instead, the new leadership team has “the intent to build and grow the company.”The Texas outfit’s new approach will be to bring in preclinical or clinical candidates with “defined value inflection points” that meet significant unmet medical needs in neurology or oncology, according to the release. “Strategic transformations are a common and often successful approach in biotechnology,” Rami Levin, who took over as CEO of CNS in January, said in the release. “With the right leadership experience and a disciplined, data-driven strategy, companies can transform their pipelines and create substantial value.”Not long after taking the helm, Levin brought on board a new chief financial officer, a chief technology officer, a chief business officer and a chief medical officer. He also wrote a letter to shareholders announcing that he was thoroughly evaluating the company’s pipeline and operations.In its most recent financial disclosure last November, CNS revealed cash reserves of about $9.9 million, which the biotech envisioned funding operations into the second half of this year.

Phase 2Executive ChangeFinancial Statement

100 Deals associated with ARC-100

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic melanoma	Phase 2	United States	Cortice Biosciences, Inc.	01 Sep 2013
Neuroblastoma recurrent	Phase 2	United States	Cortice Biosciences, Inc.	01 Dec 2011
Medulloblastoma	Phase 2	United States	Cortice Biosciences, Inc.	01 Dec 2011
Breast Cancer	Phase 2	United States	Cortice Biosciences, Inc.	16 Aug 2011
Breast Carcinoma Metastatic in the Brain	Phase 2	United States	Cortice Biosciences, Inc.	16 Aug 2011
Glioblastoma Multiforme	Phase 2	United States	Cortice Biosciences, Inc.	01 Apr 2010
Recurrent Glioblastoma	Phase 2	United States	Cortice Biosciences, Inc.	01 Apr 2010
Pancreatic carcinoma non-resectable	Phase 2	United States	Cortice Biosciences, Inc.	01 Oct 2007
Pancreatic carcinoma non-resectable	Phase 2	Spain	Cortice Biosciences, Inc.	01 Oct 2007
Metastatic Prostate Carcinoma	Phase 2	United States	Cortice Biosciences, Inc.	01 Jan 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02133846 \| NCT01966666 (Pubmed \| JAMA Neurol) Manual	Phase 1	Alzheimer Disease \| Corticobasal degeneration \| Supranuclear Palsy, Progressive	68	TPI-287	njnyxdjumk(ptwkmgirip) = clswqbsvuz rrelwfgjyu (cwtoehjpxs ) View more	Positive	01 Feb 2020
NCT02133846 \| NCT01966666 (Pubmed \| JAMA Neurol) Manual	Phase 1		68	Placebo	njnyxdjumk(ptwkmgirip) = gmapllienb rrelwfgjyu (cwtoehjpxs ) View more	Positive	01 Feb 2020
NCT01582152 (CTgov)	Phase 1/2	Recurrent Glioblastoma	12	Bevacizumab+TPI (TPI 287 160 mg/m2 + Bevacizumab)	qxtwjfccfe(mkcklsuiok) = uscpnodupa ptsfbtkrxn (bugdbexoed, ictzvehfyj - lgdiglfvum) View more	-	05 Jun 2019
NCT01582152 (CTgov)	Phase 1/2	Recurrent Glioblastoma	12	Bevacizumab+TPI (TPI 287 140 mg/m2 + Bevacizumab)	qxtwjfccfe(mkcklsuiok) = ztavixntxs ptsfbtkrxn (bugdbexoed, ltrvasvhht - mzqwxefxrh) View more	-	05 Jun 2019
NCT01332630 (CTgov)	Phase 2	Breast Carcinoma Metastatic in the Brain \| Breast Cancer	24	Dexamethasone+TPI 287+Ranitidine+Benadryl	emvzxpvbhg = bwvidkwilp bgwqjxomjs (hnraiuyprg, hffbxcxqgo - ganiunfepb) View more	-	10 Jul 2018
CB-017 (SNO2017)	Phase 1/2	Recurrent Glioblastoma unmethylated MGMT promoter	-	TPI 287	dysmwjacva(izdtsrmycx) = umepvayiao grwenpigpb (yjkxvguqwr ) View more	Positive	06 Nov 2017
NCT01933815 (ASCO 12017 \| ASCO 22017) Manual	Phase 1/2	Recurrent Glioblastoma	24	bevacizumab+TPI 287	aqrccxfkrl(wgmuxjbyoc) = ixcjeacfjo hnaltxewns (vrmsjwvhtj ) View more	Positive	05 Jun 2017
NCT01067066 (Pubmed \| Melanoma Res) Manual	Phase 1	Metastatic melanoma	21	temozolomide+TPI 287	wjfjoahrxe(dinrlatjvr) = neuropathy and six patients experienced grade III neuropathy sbcetzsejw (llyldxgxey ) View more	Positive	01 Dec 2016
SNO2016	Phase 1/2	Recurrent Glioblastoma	-	TPI 287	hrccvawnyj(pemuxefbdp) = myelosuppression (n=3) was the only drug-related grade 3/4 adverse event vzorzrflib (yjetfaxqfc )	Positive	07 Nov 2016
NCT01113463 (CTgov)	Phase 2	Glioblastoma Multiforme \| Recurrent Glioblastoma	17	TPI 287	agvfnrkllv = lhrdktvedc poaomxtirc (yurquaftba, gkmlvdyrjc - zapwooztzd) View more	-	31 Oct 2016
NCT00867568 (CTgov)	Phase 1	Recurrent Medulloblastoma \| Neuroblastoma \| Medulloblastoma	18	TPI 287	zmqtkjneed = oywejmyzno bytmsglvgr (kssacjmgki, jnjgzwbjdb - noqukyduit) View more	-	28 Oct 2016
NCT01505608 (CTgov)	Phase 1/2	Neuroblastoma recurrent \| Neuroblastoma	14	Temozolomide+Irinotecan (Arm A- Temozolomide and Irinotecan)	ladvsvbhma = gzgrgqwsfp uvfdotuhot (ahrfdqzizc, nyiiirorwo - oxjpocxesf) View more	-	28 Oct 2016
NCT01505608 (CTgov)	Phase 1/2	Neuroblastoma recurrent \| Neuroblastoma	14	Temozolomide+TPI 287+Irinotecan (Arm B- Temozolomide/Irinotecan + TPI 287)	zxlbjgeeir = sedhraygwm nvyebyduoj (cmjnhlspst, syybesnngd - fkwdxldxve)	-	28 Oct 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis